Eupraxia Pharmaceuticals initiated with RBC Outperform rating, $14 target
EPRX•RBC initiated coverage of Eupraxia Pharmaceuticals with an Outperform rating and a $14 target price.
Related News
Canaccord Genuity cuts North American Construction Group target to C$15.5 from C$24.5
NOA•
CNH to sell majority interest in construction equipment unit to Kobelco in $1 billion deal
CNH•
NAB sees Australian interest rates at peak as economy slows
NABZY•
Humana: Piper Sandler raises target price to $526 from $463
HUM•
Figure Technology Solutions, Inc.: KBW cuts target price to $37 from $45
FIGR•